-PXMD Strengthened Executive Team with Recent Appointment of Stephen D. Sheldon As Chief Financial Officer-

-Second Independent Director, Dr. John F. Coelho, Appointed to Board of Directors in May 2022-

TARRYTOWN, NY, Sept. 27, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica(PXMD.US), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies ("APT") for the treatment of disorders with intractable neurologic symptoms, today provided a corporate update after the Company's initial public offering ("IPO"), which closed on August 26, 2022.

Most recently, PaxMedica appointed Stephen D. Sheldon as Chief Financial Officer in July 2022. In May 2022, Dr. John F. Coelho...